<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03740152</url>
  </required_header>
  <id_info>
    <org_study_id>2016P002481</org_study_id>
    <nct_id>NCT03740152</nct_id>
  </id_info>
  <brief_title>Transcranial Near-Infrared Light in Healthy Subjects: a Cerebral Blood Flow Study With Diffuse Correlation Spectroscopy</brief_title>
  <acronym>NIR-Flow</acronym>
  <official_title>Transcranial Near-Infrared Light in Healthy Subjects: a Cerebral Blood Flow Study With Diffuse Correlation Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Transcranial Light Therapy involves non-invasive and invisible beams of light that increase&#xD;
      energy metabolism in the brain. Transcranial light therapy has been found to promote brain&#xD;
      metabolism. The purpose of the study is:&#xD;
&#xD;
      To asses the change in cerebral blood flow induced by the Transcranial Continuous and Pulse&#xD;
      Near-Infrared Light Therapy in healthy subjects.&#xD;
&#xD;
      To correlate with cognitive performance the change in cerebral blood flow induced by the&#xD;
      Transcranial Continuous and Pulse Near-Infrared Light Therapy in healthy subjects.&#xD;
&#xD;
      To correlate with skin pigmentation the change in cerebral blood flow induced by the&#xD;
      Transcranial Continuous and Pulse Near-Infrared Light Therapy in healthy subjects.&#xD;
&#xD;
      To assess the safety and tolerability of the Transcranial Continuous and Pulse Near-Infrared&#xD;
      Light Therapy in healthy subjects&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During study visits a clinician applies transcranial light therapy to both sides of a&#xD;
      participant's forehead for about 30 minutes. The study involves, 1 screening visit which may&#xD;
      last up to 3 hours, 3 transcranial light therapy treatment visits, and 1 posttreatment visit&#xD;
      (5 total visits to the Massachusetts General Hospital).&#xD;
&#xD;
      All eligible participants will have 1 visit with continuous light, 1 visit with pulsed light,&#xD;
      and 1 visit with sham light. Cerebral blood flow will be measured before and after each light&#xD;
      session using DCS-spectroscopy. During sham transcranial light therapy visits, the&#xD;
      transcranial light therapy device will not produce near infrared waves (e.g., light energy&#xD;
      that cannot penetrate the skin and cranium). The participant will not know which treatment is&#xD;
      received at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2017</start_date>
  <completion_date type="Actual">May 16, 2019</completion_date>
  <primary_completion_date type="Actual">May 16, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Participant receives all three types of light: continuous, pulse, and sham. They do not know when they receive each type of light, but they do know that they will receive all three.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Cerebral Blood Flow (Baseline to Week 5)</measure>
    <time_frame>5 weeks</time_frame>
    <description>Measured using Diffuse Correlation Spectroscopy (DCS) signal.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Accuracy on N-Back Task (Baseline to Week 5)</measure>
    <time_frame>5 weeks</time_frame>
    <description>The N-Back task is a measure of working memory. Participants are presented a sequence of stimuli and they must decide if the current stimulus is the same as the one presented 2 trials ago. Accuracy was measured as a percentage of correct to incorrect trials.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Treatment-Emergent Adverse Events</measure>
    <time_frame>5 weeks</time_frame>
    <description>The safety endpoints will evaluate any reported adverse events within one week from each sessions of TLT.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Cognitive Change</condition>
  <arm_group>
    <arm_group_label>Transcranial Light Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcranial Light Therapy</intervention_name>
    <description>Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)</description>
    <arm_group_label>Transcranial Light Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects age at screening will be between 18 and 70 years old (inclusive).&#xD;
&#xD;
          2. Women of child-bearing potential must use a double-barrier method for birth control&#xD;
             (e.g. condoms plus spermicide) if sexually active.&#xD;
&#xD;
          3. Subject Informed Consent obtained in writing in compliance with local regulations&#xD;
             prior to enrollment into this study.&#xD;
&#xD;
          4. The subject is willing to participate in this study for at least 5 weeks.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The subject is pregnant or lactating.&#xD;
&#xD;
          2. The subject is on any psychotropic medication.&#xD;
&#xD;
          3. Psychotherapy is exclusionary unless the subject has had at least 8 weeks of treatment&#xD;
             prior to the screening visit.&#xD;
&#xD;
          4. Any current psychiatric disorder (per SCID assessment)&#xD;
&#xD;
          5. Substance or alcohol dependence or abuse in the past 6 months.&#xD;
&#xD;
          6. History of a psychotic disorder or psychotic episode (current psychotic episode per&#xD;
             SCID assessment).&#xD;
&#xD;
          7. Bipolar affective disorder (per SCID assessment).&#xD;
&#xD;
          8. Unstable medical or neurological illness, defined as any illness which is not&#xD;
             well-controlled with standard-of-care medications (e.g., insulin for diabetes&#xD;
             mellitus, HCTZ for hypertension).&#xD;
&#xD;
          9. Suicidal or homicidal ideation as determined by SCID screening.&#xD;
&#xD;
         10. The subject has a significant skin condition (i.e., hemangioma, scleroderma,&#xD;
             psoriasis, rash, open wound or tattoo) on the subject's scalp that is found to be in&#xD;
             proximity to any of the procedure sites.&#xD;
&#xD;
         11. The subject has an implant of any kind in the head (e.g. stent, clipped aneurysm,&#xD;
             embolised Arteriovenous Malformation (AVM), implantable shunt - Hakim valve).&#xD;
&#xD;
         12. Any use of light-activated drugs (photodynamic therapy) within 14 days prior to study&#xD;
             enrollment (in US: Visudyne (verteporfin) - for age related macular degeneration;&#xD;
             Aminolevulinic Acid- for actinic keratoses; Photofrin (porfimer sodium) - for&#xD;
             esophageal cancer, non-small cell lung cancer; Levulan Kerastick (aminolevulinic acid&#xD;
             HCl) - for actinic keratosis; 5-aminolevulinic acid (ALA)- for non-melanoma skin&#xD;
             cancer)&#xD;
&#xD;
         13. Recent history of stroke (90 days).&#xD;
&#xD;
         14. Personality traits that rend the subject unsuitable for the study, based on the&#xD;
             investigators' clinical judgment.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paolo Cassano, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital Center for Anxiety and Traumatic Stress Disorders</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital- Center for Anxiety and Traumatic Stress Disorders</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>August 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2018</study_first_posted>
  <results_first_submitted>August 3, 2020</results_first_submitted>
  <results_first_submitted_qc>October 30, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 19, 2020</results_first_posted>
  <last_update_submitted>October 30, 2020</last_update_submitted>
  <last_update_submitted_qc>October 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Paolo Cassano</investigator_full_name>
    <investigator_title>Physician, Psychiatry</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 15, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT03740152/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Transcranial Light Therapy</title>
          <description>All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.&#xD;
Transcranial Light Therapy: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Transcranial Light Therapy</title>
          <description>All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.&#xD;
Transcranial Light Therapy: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="10"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.6" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Cerebral Blood Flow (Baseline to Week 5)</title>
        <description>Measured using Diffuse Correlation Spectroscopy (DCS) signal.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Light Therapy</title>
            <description>All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.&#xD;
Transcranial Light Therapy: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Cerebral Blood Flow (Baseline to Week 5)</title>
          <description>Measured using Diffuse Correlation Spectroscopy (DCS) signal.</description>
          <units>mm2/s</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.15" spread="1.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Accuracy on N-Back Task (Baseline to Week 5)</title>
        <description>The N-Back task is a measure of working memory. Participants are presented a sequence of stimuli and they must decide if the current stimulus is the same as the one presented 2 trials ago. Accuracy was measured as a percentage of correct to incorrect trials.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Light Therapy</title>
            <description>All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.&#xD;
Transcranial Light Therapy: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Accuracy on N-Back Task (Baseline to Week 5)</title>
          <description>The N-Back task is a measure of working memory. Participants are presented a sequence of stimuli and they must decide if the current stimulus is the same as the one presented 2 trials ago. Accuracy was measured as a percentage of correct to incorrect trials.</description>
          <units>accuracy percentage</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.49" spread="20.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Treatment-Emergent Adverse Events</title>
        <description>The safety endpoints will evaluate any reported adverse events within one week from each sessions of TLT.</description>
        <time_frame>5 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Transcranial Light Therapy</title>
            <description>All subjects will be administered 1 week of continuous TLT, 1 week of pulsed TLT, and 1 week of sham TLT.&#xD;
Transcranial Light Therapy: Device: LiteCure® The PhotoBioModulation-1000 (TPBM-1000)</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Treatment-Emergent Adverse Events</title>
          <description>The safety endpoints will evaluate any reported adverse events within one week from each sessions of TLT.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Collected over course of entire treatment period and follow-up (5 weeks).</time_frame>
      <desc>There were no participants that had qualities that would make them at risk for serious adverse events or all-cause mortality in this study with this pre-studied advice.</desc>
      <group_list>
        <group group_id="E1">
          <title>Transcranial Light Therapy Recipients</title>
          <description>All participants</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Weakness/fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Trouble concentrating</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Blurred vision</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Nausea/vomiting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Paolo Cassano, M.D.</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-643-9622</phone>
      <email>pcassano@mgh.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

